Ads
related to: treatment algorithm for rheumatoid arthritis in children prognosis life expectancy
Search results
Results from the WOW.Com Content Network
According to estimates, juvenile idiopathic arthritis (JIA) affects 1 to 4 out of every 1000 children, making it the most prevalent rheumatic illness in children. [ 34 ] [ 35 ] With incidence rates ranging from 0.4 to 0.8 children per 100,000 children, sJIA accounts for 10% to 20% of JIA cases.
Juvenile idiopathic arthritis (JIA), formerly known as juvenile rheumatoid arthritis (JRA), [1] is the most common chronic rheumatic disease of childhood, affecting approximately 3.8 to 400 out of 100,000 children. [3]
Clinical guidelines provide treatment recommendations dependent on the clinical characteristics. [24] The treatment of most types of juvenile arthritis include medications, physical therapy, splints and in severe cases surgery. [12] The type and intensity of the treatment is largely based upon the subtype and severity of damage of the disease. [6]
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Sulfasalazine also appears to be most effective in the short-term treatment of rheumatoid arthritis. [121] Hydroxychloroquine, in addition to its low toxicity profile, is considered effective for treatment of moderate RA symptoms. [122] Agents may be used in combination, however, people may experience greater side effects.
ACR score is a scale to measure change in rheumatoid arthritis symptoms. [1] It is named after the American College of Rheumatology. The ACR score is more often used in clinical trials than in doctor patient-relationships, as it allows a common standard between researchers. Different degrees of improvement are referred to as ACR20, ACR50, ACR70.
The RAQoL was developed by Galen Research, the University of Leeds and the Academic Hospital Maastricht, and was first published in 1997. [5] It was the first patient completed quality of life questionnaire that focused on rheumatoid arthritis [6] and is distinct from other questionnaires as it includes physical contact as a dimension of quality of life. [3]
Five-year survival rates can be used to compare the effectiveness of treatments. Use of five-year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as lung cancer, and less useful in cases with a long life expectancy, such as prostate cancer.
Ads
related to: treatment algorithm for rheumatoid arthritis in children prognosis life expectancy